Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A randomized, double-blind, placebo-controlled Phase 2 trial of leniolisib (CDZ173) in primary Sjögren's syndrome
2014-004616-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Leniolisib arm with Placebo arm (2 arms). Primary endpoint: EULAR Sjögren’s Syndrome Patient Reported Intensity (ESSPRI) change from baseline. Started Mar 2016; status: completed.
02
Drugs
leniolisib
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2014-004616-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004616-12.